Kai Markus Schneider, MD, PhD

Kai Markus Schneider, MD, PhD

University of Pennsylvania

H-index: 21

North America-United States

About Kai Markus Schneider, MD, PhD

Kai Markus Schneider, MD, PhD, With an exceptional h-index of 21 and a recent h-index of 21 (since 2020), a distinguished researcher at University of Pennsylvania, specializes in the field of Hepatology, Microbiota, Organ crosstalk, Immunology, Bile acids.

His recent articles reflect a diverse array of research interests and contributions to the field:

Prevalence of at‐risk MASH, M et ALD and alcohol‐associated steatotic liver disease in the general population

TLR9 deletion rescues cell death associated fibrosis-and hepatocarcinoma progression in models of liver injury

Crystalising the burden of steatotic liver disease—Authors' reply

Stressing the gut-brain axis

The Differential Impact of Animal and Vegetable Fat Intake on the Risk of Metabolic-dysfunction Associated Liver Disease

Microbiota modulation by dietary oat beta-glucan prevents steatotic liver disease progression

Comorbidities, mortality and metabolic profile in individuals with primary biliary cholangitis—A Phenome‐Wide‐Association‐Study

A genome-first approach to variants in MLXIPL and their association with hepatic steatosis and plasma lipids

Kai Markus Schneider, MD, PhD Information

University

Position

Postdoctoral Fellow

Citations(all)

1409

Citations(since 2020)

1353

Cited By

247

hIndex(all)

21

hIndex(since 2020)

21

i10Index(all)

24

i10Index(since 2020)

24

Email

University Profile Page

University of Pennsylvania

Google Scholar

View Google Scholar Profile

Kai Markus Schneider, MD, PhD Skills & Research Interests

Hepatology

Microbiota

Organ crosstalk

Immunology

Bile acids

Top articles of Kai Markus Schneider, MD, PhD

Title

Journal

Author(s)

Publication Date

Prevalence of at‐risk MASH, M et ALD and alcohol‐associated steatotic liver disease in the general population

Alimentary Pharmacology & Therapeutics

Carolin V Schneider

Kai Markus Schneider

Anastasia Raptis

Helen Huang

Christian Trautwein

...

2024/3/19

TLR9 deletion rescues cell death associated fibrosis-and hepatocarcinoma progression in models of liver injury

Zeitschrift für Gastroenterologie

Hannes Hatten

Leticia Colyn

Antje Mohs

Kai Markus Schneider

Ines Volkert

...

2024/1

Crystalising the burden of steatotic liver disease—Authors' reply

Carolin V Schneider

Kai Markus Schneider

Rohit Loomba

2024/5

Stressing the gut-brain axis

TheScienceBreaker

Niklas Blank

Kai Markus Schneider

Christoph Thaiss

2024/1/31

The Differential Impact of Animal and Vegetable Fat Intake on the Risk of Metabolic-dysfunction Associated Liver Disease

Zeitschrift für Gastroenterologie

Simon Schophaus

Christian Trautwein

Kai Markus Schneider

Carolin Victoria Schneider

2024/1

Microbiota modulation by dietary oat beta-glucan prevents steatotic liver disease progression

JHEP Reports

Julius W Jaeger

Annette Brandt

Wenfang Gui

Timur Yergaliyev

Angélica Hernández-Arriaga

...

2024/3/1

Comorbidities, mortality and metabolic profile in individuals with primary biliary cholangitis—A Phenome‐Wide‐Association‐Study

Liver International

Paul‐Henry Koop

Constanze Schwenzer

Jan Clusmann

Mara S Vell

Julius Jaeger

...

2024/4/25

A genome-first approach to variants in MLXIPL and their association with hepatic steatosis and plasma lipids

Hepatology Communications

Leonida Hehl

Kate T Creasy

Cecilia Vitali

Eleonora Scorletti

Katharina S Seeling

...

2024/5/1

Discriminating between MASLD and MetALD: Insights from UK Biobank Lipidomics

Zeitschrift für Gastroenterologie

Carolin Victoria Schneider

Kai Markus Schneider

2024/1

Machine learning for liver cancer risk stratification on population-level data

Zeitschrift für Gastroenterologie

Jan Clusmann

Paul Koop

Yazhou Chen

Benjamin Laevens

Kai Markus Schneider

...

2024/1

A new era for steatotic liver disease: Evaluating the novel nomenclature in the UK Biobank

Journal of Hepatology

Kai Markus Schneider

Carolin V Schneider

2024/2/1

Impact of PNPLA3 I148M on alpha-1 antitrypsin deficiency-dependent liver disease progression

Hepatology

Ines Volkert

Malin Fromme

Carolin Schneider

Lena Candels

Cecilia Lindhauer

...

2024/4/1

Exploring the tissue specific roles of FXR within the gut-liver axis: Insights from a novel mouse model

Zeitschrift für Gastroenterologie

Lina Ludwigs

Thorben Reul

Anncharlott Henniges

Ines Volkert

Mona Peltzer

...

2024/1

Metabolic Phenotype and Morbidity in Patients with Primary Biliary Cholangitis

Zeitschrift für Gastroenterologie

Paul-Henry Koop

Constanze Viktoria Schwenzer

Jan Clusmann

Wenfang Gui

Tony Bruns

...

2024/1

The enteric nervous system relays psychological stress to intestinal inflammation

Cell

Kai Markus Schneider

Niklas Blank

Yelina Alvarez

Katharina Thum

Patrick Lundgren

...

2023/6/22

An integrative experimental and computational twin modeling approach to understand clonal dynamics in the normal liver

Journal of Hepatology

Dirk Drasdo

Jieling Zhao

2023/8/1

Aspirin is associated with a reduced incidence of liver disease in men

Hepatology Communications

Mara Sophie Vell

Arunkumar Krishnan

Kirk Wangensteen

Marina Serper

Katharina Sophie Seeling

...

2023/10/1

Colitis ameliorates cholestatic liver disease via suppression of bile acid synthesis

Nature Communications

Wenfang Gui

Mikal Jacob Hole

Antonio Molinaro

Karolina Edlund

Kristin K Jørgensen

...

2023/6/6

Omega-3 intake is associated with liver disease protection

Frontiers in Public Health

Mara Sophie Vell

Kate Townsend Creasy

Eleonora Scorletti

Katharina Sophie Seeling

Leonida Hehl

...

2023/7/19

Association of statin use with risk of liver disease, hepatocellular carcinoma, and liver-related mortality

JAMA Network Open

Mara Sophie Vell

Rohit Loomba

Arunkumar Krishnan

Kirk J Wangensteen

Jonel Trebicka

...

2023/6/1

See List of Professors in Kai Markus Schneider, MD, PhD University(University of Pennsylvania)